PRCT — PROCEPT BioRobotics Corporation Stock Price, Chart & AI Report

Negative Sep 1, 2026 • 20:56 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Photronics, Inc. of Class Action Lawsuit and Upcoming Deadlines – PLAB

Pomerantz Law Firm has filed class action lawsuits against Photronics, Inc. and PROCEPT BioRobotics Corporation, alleging securities fraud and unlawful business practices. Photronics' stock fell 36.4% on May 28, 2026, following disappointing Q2 fiscal 2026 results with revenue and earnings below projections and an 11% sequential decline in IC revenue. The deadline to join the Photronics class action as Lead Plaintiff is September 4, 2026.

PLAB PRCT class action lawsuit securities fraud Photronics PROCEPT BioRobotics stock price decline financial results

Sentiment note

Company is subject to investigation and class action lawsuit by Pomerantz LLP for alleged securities fraud and unlawful business practices, indicating potential investor losses and legal exposure.

Negative Sep 1, 2026 • 20:50 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines – PRCT

Pomerantz Law Firm has filed a class action lawsuit against PROCEPT BioRobotics Corporation, alleging securities fraud and unlawful business practices. The lawsuit stems from the company's repeated mismanagement of inventory and missed sales guidance. PROCEPT failed to disclose that handpiece sales significantly exceeded procedures, resulting in over 10,000 units of excess field inventory. The company's stock declined sharply following three earnings announcements in 2025-2026, with the most recent showing a 30% sequential decline in quarterly handpiece sales. Investors have until September 22, 2026, to request Lead Plaintiff status.

PRCT class action lawsuit securities fraud inventory mismanagement missed guidance stock decline handpiece sales field inventory

Sentiment note

Company faces class action lawsuit for alleged securities fraud and failure to disclose material information about excess inventory. Multiple earnings misses, significant stock price declines (16%, 10%, and 18% over respective two-day periods), and admission of poor inventory management practices indicate serious operational and disclosure failures.

Negative Sep 1, 2026 • 19:59 UTC GlobeNewswire Inc. • Portnoy Law Firm

Portnoy Law Firm Announces Class Action on Behalf of PROCEPT BioRobotics Corporation Investors

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false and misleading statements regarding its business operations. The company allegedly used undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess field inventory of over 10,000 units, and failed to disclose risks that prevented it from achieving 2025 guidance. Stock prices fell significantly following earnings announcements in August, November 2025, and February 2026 that revealed lower-than-expected sales and inventory management issues.

PRCT class action lawsuit securities fraud false statements inventory management handpiece sales stock decline earnings miss

Sentiment note

The company is accused of making materially false and misleading statements, using undisclosed discount programs to artificially inflate sales, accumulating excess inventory of 10,000+ units, missing earnings guidance, and experiencing significant stock price declines (16%, 10%, and 18%) following successive earnings announcements revealing operational and financial deterioration.

Negative Aug 31, 2026 • 18:30 UTC GlobeNewswire Inc. • Glancy Prongay Wolke & Rotter Llp

Deadline Alert: PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about its business between February 2024 and February 2026. The company allegedly used an undisclosed discount program to artificially inflate handpiece sales, creating excess inventory of over 10,000 units. Stock prices fell significantly following three earnings announcements revealing lower-than-expected sales and inventory issues. Shareholders have until September 22, 2026 to file lead plaintiff motions.

PRCT securities fraud class action lawsuit handpiece sales inventory overstatement discount program stock price decline financial misstatement

Sentiment note

The company is accused of securities fraud involving material misstatements about business operations and financial condition. Undisclosed discount programs artificially inflated sales figures, leading to excess inventory of 10,000+ units. Stock declined 13.35%, 9.74%, and 15.12% on three separate earnings announcements, with cumulative shareholder losses.

Negative Aug 30, 2026 • 22:53 UTC GlobeNewswire Inc. • Rosen Law Firm

PRCT FINAL DEADLINE: ROSEN, REGARDED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT

Rosen Law Firm reminds investors of the September 22, 2026 lead plaintiff deadline in a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its discount programs, handpiece unit sales, and revenue guidance. The company allegedly used undisclosed bulk order discounts that artificially inflated sales figures and created excess inventory of over 10,000 units, exposing the company to material operational and financial risks.

PRCT securities class action PROCEPT BioRobotics lead plaintiff deadline discount program handpiece sales revenue guidance inventory overstocking

Sentiment note

The company is accused of making materially false and misleading statements about sales and revenues through undisclosed discount programs that artificially inflated figures, created excess inventory, and lacked a reasonable basis for guidance. These allegations indicate significant corporate misconduct and financial misrepresentation.

Negative Aug 30, 2026 • 22:29 UTC GlobeNewswire Inc. • Rosen Law Firm

BlackRock Investor News: If You Have Suffered Losses in BlackRock, Inc. Mutual Funds, You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities class action claims against BlackRock, Inc., PROCEPT BioRobotics Corporation, and TruBridge, Inc., alleging materially misleading business information was issued to investors. The firm is seeking to recover investor losses through contingency fee arrangements with no out-of-pocket costs for participants.

BLK DIVB PRCT securities class action investor losses misleading information contingency fee mutual funds

Sentiment note

Company is subject to a securities class action with an important deadline, indicating allegations of investor harm and potential securities violations.

Negative Aug 28, 2026 • 14:54 UTC GlobeNewswire Inc. • Kaplan Fox & Kilsheimer Llp

Kaplan Fox Reminds Investors of a Securities Class Action Against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) – Deadline is September 22, 2026

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 to February 25, 2026). The complaint claims the company misrepresented that the differential between handpiece sales and procedures remained consistent, when in fact their sales tactics pulled forward demand artificially. The deadline to serve as lead plaintiff is September 22, 2026.

PRCT class action lawsuit securities fraud PROCEPT BioRobotics handpiece sales revenue inflation discount program lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding sales practices and revenue recognition. The allegations suggest deliberate concealment of discount programs that artificially inflated reported sales figures, which constitutes securities fraud and indicates serious corporate governance and disclosure failures.

Negative Aug 26, 2026 • 12:45 UTC GlobeNewswire Inc. • Kaplan Fox & Kilsheimer Llp

Kaplan Fox Notifies Investors of Cogent Communications Holdings, Inc. (NASDAQ: CCOI) of the Lead Plaintiff Deadline on September 21, 2026

Kaplan Fox has filed class action lawsuits against Cogent Communications Holdings, PROCEPT BioRobotics, and EquipmentShare.Com Inc. The primary case involves Cogent, where investors claim the company misrepresented demand for optical wavelengths and inflated order backlogs that never materialized into paying customers. Following CEO David Schaeffer's admission of customer delays in wavelength installations on May 4, 2026, Cogent's stock fell 29% to $16.37 per share. Lead plaintiff deadlines range from September 21-22, 2026.

CCOI PRCT EQPT class action lawsuit securities fraud investor losses misrepresentation optical wavelengths

Sentiment note

Class action lawsuit has been filed against the company, though specific allegations are not detailed in the article. The mere filing of such litigation indicates investor concerns and potential securities violations.

Negative Aug 26, 2026 • 02:34 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

PROCEPT BioRobotics faces a securities class action lawsuit for failing to disclose material inventory issues. The company revealed on February 25, 2026 that handpiece sales had materially exceeded procedures since Q1 2023, resulting in over 10,000 units of excess field inventory. This disclosure caused the stock to plummet approximately 18% in two days, from $27.84 to $22.69 per share, as quarterly handpiece sales declined nearly 30% and the company missed annual revenue guidance by tens of millions of dollars. Investors who purchased shares between February 28, 2024 and February 25, 2026 have until September 22, 2026 to file lead plaintiff applications.

PRCT securities fraud class action lawsuit inventory disclosure stock decline handpiece sales revenue guidance miss

Sentiment note

The company is facing securities fraud allegations for failing to disclose material inventory issues that led to a significant 18% stock price decline, missed revenue guidance by tens of millions of dollars, and a 30% sequential decline in quarterly handpiece unit sales.

Negative Aug 25, 2026 • 21:49 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines – PRCT

Pomerantz Law Firm has filed class action lawsuits against PROCEPT BioRobotics Corporation for alleged securities fraud. The lawsuit stems from PROCEPT's repeated missed sales guidance, accumulation of excess field inventory exceeding 10,000 units, and significant stock price declines following earnings announcements in August 2025, November 2025, and February 2026. Investors have until September 22, 2026, to join the class action.

PRCT class action lawsuit securities fraud missed guidance inventory buildup stock decline handpiece sales investor losses

Sentiment note

Company faced multiple consecutive quarters of missed sales guidance, accumulated excess inventory of 10,000+ units, failed to properly manage customer inventory levels, and experienced significant stock price declines (16%, 10%, and 18%) following earnings announcements. These factors indicate operational failures and potential securities fraud.

Negative Aug 24, 2026 • 23:34 UTC GlobeNewswire Inc. • Rosen Law Firm

PRCT FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT

Rosen Law Firm is reminding investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) of the September 22, 2026 lead plaintiff deadline for a securities class action. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales, created excess inventory of over 10,000 units, and made unachievable 2025 guidance.

PRCT securities class action lead plaintiff deadline false statements discount program inventory overstocking revenue inflation handpiece sales

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements regarding sales practices, artificially inflated revenues through undisclosed discount programs, excess inventory accumulation exceeding 10,000 units, and unachievable financial guidance. These allegations indicate significant operational and financial misconduct.

Positive Aug 18, 2026 • 22:11 UTC The Motley Fool • Brendan Coffey

Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?

Procept BioRobotics CEO Larry Wood purchased 23,900 shares (~$498,000) through a trust on August 7, 2026, expanding his beneficial stake to 338,103 shares. The purchase occurred as the stock declined 48% over the past year, but comes after the company reported 19% Q2 sales growth and Wood's reorganization efforts. Insider purchases are typically viewed as bullish signals, suggesting management confidence in the company's turnaround prospects despite ongoing net losses of $109.8 million on $337.3 million in trailing revenue.

PRCT insider buying CEO purchase medical robotics surgical technology stock decline management confidence Aquablation therapy

Sentiment note

CEO's significant insider purchase of ~$498,000 in shares signals management confidence in the company's direction. The purchase follows Q2 sales growth of 19% and a strategic reorganization led by Wood. While the stock is down 48% year-over-year and the company remains unprofitable, insider buying is historically predictive of share price appreciation within 30 days and demonstrates management's conviction in long-term profitability prospects.